CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 120 enrolled
Drug / intervention
Liposomal Bupivacaine +2 moredrug
Likely dose
Liposomal Bupivacaine 20 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03859635
NCT03859635Phase 3Completed
CompareCT.gov

Randomized Prospective Study Comparing Exparel Erector Spinae Plane Block vs Simple Bupivacaine Erector Spinae Plane Block vs Exparel Surgeon Infiltration for Postoperative Analgesia Following Video-assisted Thoracoscopic Surgery

Indiana University·interventional·Posted Mar 1, 2019·Updated Feb 28, 2025

In Brief

A Phase 3 clinical trial evaluating Liposomal Bupivacaine, Bupivacaine, 0.25%, and 1 other intervention for Pain, Postoperative and 2 related conditions. Completed, enrolled 120 participants across 1 site.

Detailed Summary

The study is comparing the difference between erector spinae block and surgeon infiltration after VATS (Video Assisted Thoracoscopic Surgery). The outcomes measured are pain scores, opioid usage, opioid side effects, and patient satisfaction.We are also also studying the effectiveness of liposomal bupivacaine (EXPAREL) in a block by randomizing patients to both EXPAREL erector spinae block and simple bupivacaine erector spinae block.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Postoperative, Thoracic, Acute Pain
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 1, 2019
Enrollment StartFeb 7, 2019
Primary CompletionNov 6, 2022
Study CompletionNov 7, 2022
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 7.3 years ago

Interventions

Liposomal Bupivacainedrug

20 ml

Bupivacaine, 0.25%drug

10 ml

Bupivacaine, 0.5%drug

30 ml